BSEGKB Ophthalmics LtdHighNeutral
Announced Fri, 30 May · 21:13 IST

The meeting of the Board of Directors was held on May 30, 2025 which inter-alia approved and took on record the Audited Standalone and Consolidated Financials Results of the Company for ....

Revenue DeclinePat NegativeNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The Board of Directors approved the Audited Standalone and Consolidated Financial Results for Q4 and FY ended March 31, 2025. Statutory Auditor MSKA & Associates issued an Audit Report with an unmodified (clean) opinion. The Board decided to pass over (skip) the dividend for FY 2024-25, meaning shareholders will not receive any dividend this year. Key standalone numbers show revenue of Rs 3,325.79 lakhs (down from Rs 3,563.11 lakhs in FY24) and a net loss of Rs 217.95 lakhs (wider than Rs 171.51 lakhs loss in FY24), with EPS of negative Rs 4.33. The company reported negative operating cash flow of Rs 103.58 lakhs for FY25, compared to a positive Rs 136.31 lakhs last year. The AGM is scheduled for August 21, 2025 via video conferencing.

Likely market impact

Shareholders face a double negative this announcement: no dividend for the year and a deeper loss with weaker operating cash generation. The clean audit opinion is a relief, but the deteriorating financials and continued losses could weigh on investor sentiment and the stock price.